Teleflex Incorporated (NYSE:TFX) – Equities researchers at Leerink Swann issued their Q1 2018 earnings estimates for Teleflex in a report released on Tuesday. Leerink Swann analyst R. Newitter expects that the medical technology company will earn $2.00 per share for the quarter. Leerink Swann has a “Outperform” rating and a $266.00 price objective on the stock. Leerink Swann also issued estimates for Teleflex’s Q2 2018 earnings at $2.40 EPS, Q3 2018 earnings at $2.52 EPS and Q4 2018 earnings at $2.67 EPS.

Other equities research analysts also recently issued research reports about the company. Needham & Company LLC raised their target price on Teleflex from $228.00 to $237.00 and gave the company a “buy” rating in a report on Tuesday, September 5th. Piper Jaffray Companies began coverage on Teleflex in a report on Friday, November 10th. They issued an “overweight” rating and a $295.00 target price on the stock. Morgan Stanley raised Teleflex from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $220.00 to $274.00 in a report on Wednesday, September 6th. KeyCorp reaffirmed a “hold” rating on shares of Teleflex in a report on Wednesday, September 6th. Finally, Zacks Investment Research raised Teleflex from a “hold” rating to a “buy” rating and set a $261.00 target price on the stock in a report on Tuesday, September 12th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $274.44.

Shares of Teleflex (NYSE:TFX) traded up $1.54 during mid-day trading on Thursday, hitting $255.77. The company’s stock had a trading volume of 178,000 shares, compared to its average volume of 265,603. The firm has a market cap of $11,452.88, a P/E ratio of 31.42, a PEG ratio of 2.18 and a beta of 1.09. Teleflex has a 52-week low of $157.80 and a 52-week high of $271.23. The company has a debt-to-equity ratio of 0.88, a quick ratio of 3.70 and a current ratio of 4.72.

Teleflex (NYSE:TFX) last issued its earnings results on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.01 by $0.11. The firm had revenue of $534.70 million for the quarter, compared to the consensus estimate of $522.94 million. Teleflex had a return on equity of 16.27% and a net margin of 12.41%. The company’s revenue was up 17.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.80 EPS.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Parametric Portfolio Associates LLC lifted its holdings in Teleflex by 7.6% during the 3rd quarter. Parametric Portfolio Associates LLC now owns 133,455 shares of the medical technology company’s stock worth $32,292,000 after buying an additional 9,399 shares during the period. Public Employees Retirement System of Ohio lifted its holdings in Teleflex by 59.1% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 32,728 shares of the medical technology company’s stock worth $7,919,000 after buying an additional 12,155 shares during the period. IFM Investors Pty Ltd acquired a new position in Teleflex during the 3rd quarter worth about $338,000. Coldstream Capital Management Inc. acquired a new position in Teleflex during the 3rd quarter worth about $226,000. Finally, California Public Employees Retirement System lifted its holdings in Teleflex by 5.3% during the 3rd quarter. California Public Employees Retirement System now owns 102,182 shares of the medical technology company’s stock worth $24,725,000 after buying an additional 5,182 shares during the period. 88.97% of the stock is currently owned by hedge funds and other institutional investors.

In other Teleflex news, CEO Benson Smith sold 2,000 shares of Teleflex stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $258.10, for a total transaction of $516,200.00. Following the transaction, the chief executive officer now directly owns 76,634 shares of the company’s stock, valued at approximately $19,779,235.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Stephen K. M.D. Klasko sold 200 shares of Teleflex stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $237.18, for a total value of $47,436.00. Following the transaction, the director now directly owns 8,080 shares in the company, valued at $1,916,414.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,600 shares of company stock worth $665,076. 2.39% of the stock is currently owned by company insiders.

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 15th. Investors of record on Wednesday, November 15th were issued a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 0.53%. The ex-dividend date was Tuesday, November 14th. Teleflex’s dividend payout ratio (DPR) is 24.82%.

TRADEMARK VIOLATION NOTICE: “Teleflex Incorporated (TFX) Forecasted to Post Q1 2018 Earnings of $2.00 Per Share” was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/teleflex-incorporated-tfx-forecasted-to-post-q1-2018-earnings-of-2-00-per-share/1776372.html.

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.